(CercleFinance.com) – Valbiotis announces the “large success” of a Phase II/III clinical study on TOTUM•63 confirming the efficacy of this treatment in type 2 diabetes on the criterion of reduction of fasting blood sugar 2 or 3 doses per day.
According to Sébastien Peltier, co-founder and Chairman of the Executive Committee of Valbiotis, believes that the results of this study represent ‘a major advance in the fight against diabetes and its complications for people with prediabetes and untreated type 2 diabetes (early stage )’.
‘We have provided unequivocal clinical proof that TOTUM•63 is a promising solution for millions of people around the world, helping to prevent the progression to type 2 diabetes’, he adds.
These positive results trigger a lump sum payment of 4 million Swiss francs from Nestlé Health Science as part of the global strategic partnership.
This payment will be made upon submission of the full study report during the summer.